Examples of 'apoa-i' in a sentence
Meaning of "apoa-i"
ApoA-I is a protein that plays a key role in the metabolism of lipids and is associated with high-density lipoproteins (HDL)
How to use "apoa-i" in a sentence
Basic
Advanced
apoa-i
No antibodies to ApoA-I were detected following single dose administration.
Also provided herein are recombinant ApoA-I expression vectors.
The ApoA-I agonists of the invention increase cellular cholesterol efflux.
Also disclosed herein are recombinant ApoA-I expression vectors.
The mammalian host cells disclosed herein can be used to produce ApoA-I.
A variety of purification techniques for ApoA-I have been developed.
Functional apoA-I is essential for removal of cellular cholesterol and for cholesterol homeostasis.
A specific example of such an apolipoprotein is ApoA-I.
The maximum changes in plasma ApoA-I are bolded for each dose.
The ApoA-I agonists of the invention can be further defined by way of preferred embodiments.
Optionally it is proposed to concentrate ApoA-I by adsorption onto a second ion exchange resin.
The method comprises administering to said individual a therapeutically efficient amount of ApoA-I or rHDL.
Statistical results show a significant difference in apoA-I levels after a four week treatment.
In view of these drawbacks, attempts have been made to prepare peptides that mimic ApoA-I.
In addition, various experimental manipulations to increase production of ApoA-I are associated with reduced atherogenicity.
See also
More specifically, the present disclosure relates to methods of obtaining highly purified ApoA-I.
In rabbits, repeated infusions of apoA-I inhibited the progression of atherosclerosis and reduced lesion size.
Such a mechanism is consistent with the known action of the apoA-I mimetic peptides.
Third, direct evidence for the role of ApoA-I was obtained from experiments involving transgenic animals.
The present disclosure also provides methods of producing mature, biologically active ApoA-I.
These experiments demonstrate the ability of the ApoA-I agonists of the invention to increase HDL-cholesterol.
The invention provides novel and advantageous conditions for precipitating ApoA-I from suspensions.
The results show that administration of the ApoA-I agonists increases serum concentration of HDL-like particles.
The methods of the present invention provide improved procedures for preparing up-regulators of ApoA-I expression.
ApoA-I administration to transgenic mice delays formation of atherosclerotic lesions.
There are several different ways to purify ApoA-I from HDL, including solvent extraction.
ApoA-I mimetics and other peptides for expression in plants.
This distribution pattern resembles what has been reported for ApoA-I and HDL.
ApoA-I can be lyophilized by a variety of procedures known in the art.
The compounds, and compositions of the invention can be used to Increase expression of ApoA-I.
ApoA-I peptide agonists which exhibit large therapeutic indices are preferred.
Contaminating proteins can be bound to the column while AAT and ApoA-I flow through.
Up-regulation of ApoA-I is considered to be a useful strategy in treatment of atherosclerosis and CVD.
Nicotinic acid reduces apoA-I catabolism.
The precipitated ApoA-I can be separated from the AAT containing solution.
A method according to claim 1 wherein said peptide is an ApoA-I analogue.
ApoA-I may then be aprotective blood-borne factor involved in the RIPreC mechanism.
The methods of the invention for purifying ApoA-I and AAT are suitable for large-scale purification.
ApoA-I injected before myocardial ischemia in rats significantly reduced myocardial infarct size.
In some embodiments, ApoA-I can be bound to fumed silica.
ApoA-I as eluted from fumed silica can then be further purified as described above.
Activity of ApoA-I mimetic peptides.
ApoA-I can be recovered from any fraction of blood plasma that contains the protein.
Alternatively, the insoluble ApoA-I material can be separated by centrifugation.
ApoA-I is one of the natural cofactors for LCAT.
In these embodiments, the ApoA-I is secreted from the cells.
HDL apoA-I is the principal catalytic activator for LCAT.
In some embodiments, the nucleotide sequence encoding ApoA-I is human.
We showed that the apoA-I mimetic peptide 6F could be expressed in transgenic tomato plants.
For high-yield production, stable expression of ApoA-I is preferred.
